Drugs / Spikogen

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT06355232 May 2024 → Dec 2025 overdue COVID-19, influenza Vaxine Pty Ltd Recruiting No outcome recorded
Phase 1 NCT04428073 Jul 2020 → Jul 2021 COVID-19 GeneCure Biotechnologies Unknown No outcome recorded
Phase 1 NCT04453852 Jun 2020 → Feb 2021 COVID-19 Vaxine Pty Ltd Completed No outcome recorded
Phase 32 trials
Phase 3 NCT05542862 Sep 2022 → Dec 2023 COVID-19 Vaxine Pty Ltd Completed No outcome recorded
Phase 3 NCT05279456 Aug 2022 → Dec 2023 COVID-19 Vaxine Pty Ltd Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT05148871 Comparator Mar 2022 → Feb 2023 overdue COVID-19 Vaxine Pty Ltd Active not recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Spikogen SpikoGen® vaccine was licensed for use in the Middle East as a primary vaccine course in adults in October 2021.” NCT06355232
4

Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine” NCT05279456

Spikogen® vaccine is an Advax-CpG55.2 adjuvanted recombinant protein vaccine” NCT06355232

NCT05542862

NCT05148871

Known as Covax-19 “Spikogen, also known under the Covax-19 tradename in Australia, is based on recombinant SARS-COV-2 spike protein” NCT05148871
3

“Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine” NCT05279456

“This is a study to test a new vaccine (Covax-19) against COVID-19.” NCT04453852

NCT04428073

Known as Spikogen vaccine Spikogen vaccineNCT05279456
Modality Vaccine “Therapeutic vaccine for SARS-CoV-2 infection” NCT04428073
Route Intramuscular “sterile solution for intramuscular injection” NCT04453852